MD Anderson Research Highlights for December 13, 2023
Â鶹ӳ» MD Anderson Cancer Center¡¯s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson¡¯s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
Recent developments at MD Anderson include a novel blood-based test to predict lung cancer relapses...
ASH: Mantle cell lymphoma patients see improved outcomes with oral combination of ibrutinib and venetoclax
ABSTRACT: LBA-2
The targeted therapy combination of ibrutinib and venetoclax significantly improved progression-free survival (PFS)...
ASH: Novel combination therapy significantly reduces spleen volume in patients with myelofibrosis
ABSTRACT: 620
Combining the JAK inhibitor ruxolitinib with the BCL-xL inhibitor navitoclax was twice as effective in reducing enlarged...
ASH: Targeted oral therapy reduced disease burden and improved symptoms for patients with rare blood disorder
ABSTRACT: 77
The targeted therapy bezuclastinib was safe and rapidly reduced markers of disease burden while also improving symptoms for patients with a rare blood disorder called nonadvanced system mastocytosis, according to results of the Phase II SUMMIT trial reported by researchers at Â鶹ӳ» MD Anderson Cancer Center.
The findings, presented today at the 2023 American Society of Hematology (ASH) Annual...
ASH: Novel menin inhibitors show promise for patients with advanced acute myeloid leukemias
ABSTRACTS: 57, 58
Two clinical trials led by researchers from Â鶹ӳ» MD?Anderson?Cancer Center demonstrated...
SABCS: Combining ribociclib with hormone therapy improved patient outcomes in early-stage breast cancer
ABSTRACT: GA03-03
Targeted treatment with ribociclib plus hormone therapy provided significant invasive disease-free survival (iDFS...
MD Anderson and Rigel Pharmaceuticals announce strategic alliance to advance olutasidenib in AML and other cancers
Â鶹ӳ» MD Anderson Cancer Center and Rigel Pharmaceuticals, Inc.?today announced a multi-year strategic development...
SABCS: Studies suggest novel targeted therapies may benefit patients with metastatic HR+/ HER2- breast cancer
ABSTRACTS: RF01-04 and RF01-07
Two studies led by researchers at Â鶹ӳ» MD Anderson Cancer Center demonstrated clinical...
MD Anderson Research Highlights: ASH 2023 Special Edition
ABSTRACTS: 162, 309, 322, 364, 741, 774, 856, 983
SAN DIEGO ¨D Â鶹ӳ» MD Anderson Cancer Center¡¯s Research Highlights...
MD Anderson, TACC and the Oden Institute announce funding for the next round of collaborative cancer research projects
Â鶹ӳ» MD Anderson Cancer Center, the Oden Institute for Computational Engineering and Sciences and the?Texas Advanced...
MD Anderson¡¯s Katy Rezvani, M.D., receives 2023 Honorific Award from the American Society of Hematology
Katy Rezvani, M.D., Ph.D.,?professor of?Stem Cell Transplantation & Cellular Therapy?at Â鶹ӳ» MD Anderson...